Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4345654 | 0.95 | RORC (0.43) | PTPN1RORCKCNH2MCHR1ACACB | |
| SCHEMBL4353675 | 0.94 | RORC (0.44) | PTPN1RORCKCNH2MCHR1ACACB | |
| SCHEMBL4351876 | 0.92 | FAAH (0.45) | PTPN1RORCACACBFAAH | |
| SCHEMBL4344611 | 0.92 | PTPN1 (0.42) | PTPN1RORCS1PR1KCNJ1S1PR5 | |
| SCHEMBL4348446 | 0.92 | KCNJ1 (0.39) | PTPN1RORCKCNH2MCHR1ACACB | |
| SCHEMBL4352026 | 0.90 | S1PR5 (0.49) | PTPN1RORCS1PR1S1PR5HRH3 | |
| SCHEMBL4348326 | 0.89 | KCNH2 (0.50) | KCNH2MCHR1ACACBGPR119HRH3 | |
| SCHEMBL14403832 | 0.89 | KCNH2 (0.41) | PTPN1RORCKCNH2MCHR1KCNJ1 | |
| SCHEMBL4352087 | 0.88 | DRD4 (0.39) | PTPN1RORCS1PR1ACACBKCNJ1 | |
| SCHEMBL4350493 | 0.87 | MMP1 (0.43) | RORCKCNH2MCHR1S1PR1KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010485-B1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | PROSIDION LTD (GB) | 2012-10-17 | — | — | EP | claimed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | claimed |
| EP-2010485-B1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | PROSIDION LTD (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | PROSIDION LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| WO-2007116230-A1 | AZETIDINE DERIVATIVES AS G-PROTEIN COUPLED RECEPTOR (GPR119 ) AGONISTS | PROSIDION LTD (GB) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281076-A1 | Azetidine Derivatives as G-Protein Coupled Receptor (GPR119) Agonists | GPR119, GPR39, GIPR | PTPN1 888/4885RORC 728/4885KCNH2 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.